514 related articles for article (PubMed ID: 31852779)
1. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
Jones HG; Ritschel T; Pascual G; Brakenhoff JPJ; Keogh E; Furmanova-Hollenstein P; Lanckacker E; Wadia JS; Gilman MSA; Williamson RA; Roymans D; van 't Wout AB; Langedijk JP; McLellan JS
PLoS Pathog; 2018 Mar; 14(3):e1006935. PubMed ID: 29509814
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
Nuñez Castrejon AM; O'Rourke SM; Kauvar LM; DuBois RM
J Virol; 2022 Apr; 96(7):e0220121. PubMed ID: 35266806
[TBL] [Abstract][Full Text] [Related]
4. Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains.
Lee J; Klenow L; Coyle EM; Golding H; Khurana S
PLoS Pathog; 2018 Aug; 14(8):e1007262. PubMed ID: 30142227
[TBL] [Abstract][Full Text] [Related]
5. Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies.
Fedechkin SO; George NL; Wolff JT; Kauvar LM; DuBois RM
Sci Immunol; 2018 Mar; 3(21):. PubMed ID: 29523582
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
7. Alternative conformations of a major antigenic site on RSV F.
Jones HG; Battles MB; Lin CC; Bianchi S; Corti D; McLellan JS
PLoS Pathog; 2019 Jul; 15(7):e1007944. PubMed ID: 31306469
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
9. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
[TBL] [Abstract][Full Text] [Related]
10. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.
Mousa JJ; Kose N; Matta P; Gilchuk P; Crowe JE
Nat Microbiol; 2017 Jan; 2():16271. PubMed ID: 28134924
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
12. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
[TBL] [Abstract][Full Text] [Related]
13. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
Zhu Q; Lu B; McTamney P; Palaszynski S; Diallo S; Ren K; Ulbrandt ND; Kallewaard N; Wang W; Fernandes F; Wong S; Svabek C; Moldt B; Esser MT; Jing H; Suzich JA
J Infect Dis; 2018 Jul; 218(4):572-580. PubMed ID: 29617879
[TBL] [Abstract][Full Text] [Related]
16. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
Harshbarger W; Abeyrathne PD; Tian S; Huang Y; Chandramouli S; Bottomley MJ; Malito E
MAbs; 2021; 13(1):1955812. PubMed ID: 34420474
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.
Kishko M; Catalan J; Swanson K; DiNapoli J; Wei CJ; Delagrave S; Chivukula S; Zhang L
Virology; 2020 Nov; 550():21-26. PubMed ID: 32866728
[TBL] [Abstract][Full Text] [Related]
18. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
